GB2210789A

GB2210789A - Topical application for skin care

Info

Publication number: GB2210789A
Application number: GB8723826A
Authority: GB
Inventors: R Ian Donald Morrison
Original assignee: MORRISON DR IAN DONALD
Current assignee: MORRISON DR IAN DONALD
Priority date: 1987-10-10
Filing date: 1987-10-10
Publication date: 1989-06-21
Also published as: GB8723826D0

Abstract

A topical composition for skin care comprises a rubifacient and vasodilatory agent mixed with a keratolytic and desquamating agent in a compatible base. The rubifacient and vasodilatory agent is preferably a nicotinic acid derivative, such as nicotinic acid or methyl nicotinate, at a concentration of between 0.01% and 20%. The keratolytic and desquamating agent is preferably a peroxide, such as benzoyl peroxide, at a concentration of between 1% and 30%. The composition is used for treatment of greasy skin, acne, sun-damaged skin and also wrinkled and ageing skin.

Description

TOPICAL APPLICATION FOR SKIN CARE The present application relates to a topical application for use in skin care. Many preparations for skin care have been previously used or proposed and the object of this invention is to provide a topical application for treating acne, greasy skin, sun damaged skin, and also wrinkled and ageing skin.

According to the invention a topical application for skin care comprises a rubifacient and vasodilatory agent mixed with a keratolytic and desquamating agent in a compatible base to a strength appropriate to an individual's requirements. The base may be, for instance, any suitable cream, ointment, gel or solvent.

The rubifacient and vasodilatory agent is preferably a nicotinic acid derivative, such as nicotinic acid at a concentration of between .01 and 20. Martindale, 28th Edition 1982 : 9253Z page 1626, lists other suitable nicotinates, particularly the group of nicotinates including methyl nicotinate, benzyl nicotinate, ethyl nicotinate, butoxyethyl nicotinate and thurfyl nicotinate.

The nicotinic acid derivative may alternatively be taken from this group of nicotinates again at a concentration of between .01 p and 20%. This range of concentrations for the above group of nicotinates and for nicotinic acid covers the normal maximum and minimum concentrations that are useful but it will be appreciated that the optimum concentration will depend on the individual patient and the skin condition to be treated. I have found that concentrations between .1 and 5% are particularly effective for general use and that a concentration of between 1% and 2% is the most effective for general use.

The keratolytic and desquamating agent is preferably a peroxide, such as benzoyl peroxide, at a concentration of between 1% and 30%. I have found that a concentration of between 1% and 20% is particularly effective for general use.

Nicotinic acid and its derivatives are used in various proprietary preparations dispensed as tablets or by injection or by local application, and are typically used with vitamin A to treat vitamin deficiency, with acetomenaphthone to treat chilblains and, as a rubifacient, in the treatment of sprains, joint and muscular pain and also rheumatic conditions. Nicotinic acid is an essential component of two intracellular enzymes, di- and tri-phosphopyridine nucleotide (DPN and TPN) which are essential components of all cells including skin. Benzoyl peroxide is typically used as an antiseptic keratolytic and desquamating agent in many preparations for the treatment of acne.

A typical course of treatment comprises the use of a series of cream ointments of increasing strengths over a period of several weeks as follows: Strength 1 An initial cream containing 2% nicotinic acid and 1% benzoyl peroxide in aqueous cream with cetyl alcohol and cetomacrogol emulsifying wax.

Strength 2 An initial cream containing 2% nicotinic acid and 2. 5% benzoyl peroxide in aqueous cream with cetyl alcohol and cetomacrogol emulsifying wax.

Strength 5 An initial cream containing 2% nicotinic acid and 5% benzoyl peroxide in aqueous cream with cetyl alcohol and cetomacrogol emulsifying wax.

Strength 10 An initial cream containing 2% nicotinic acid and 10% benzoyl peroxide in aqueous cream with cetyl alcohol and cetomacrogol emulsifying wax.

The actual strengths of all applications must of course be selected to suit the patient's skin condition.

The immediate effects of such a course of treatment are that the patient experiences a glowing feeling and improved circulation to the skin due to the rubifacient and vasodilatory properties of the nicotinic acid, whilst dead skin cells and surface waste are cleared by the desquamatory and keratolytic properties of the benzoyl peroxide, thereby allowing the nicotinic acid to penetrate and nourish the skin.

The antiseptic properties of the benzoyl peroxide enhance the cleansing of the skin and inhibit infection.

The effects of such a course of treatment are complex and influence the skin cells both from the inside and the outside. As a generalisation, cleansing of the skin cells by removal of dead cells together with wastes and waste metabolites is caused externally by the desquamating and keratolytic properties of the benzoyl peroxide whilst the increased blood supply, caused by the vasodilatory property of the nicotinic acid, similarly cleanses the skin cells internally. At the same time, regeneration of the remaining skin cells is promoted externally by the antiseptic property of the benzoyl peroxide and the nourishment of the skin due to its penetration by the nicotinic acid, and internally by the increased oxygenation and nourishment of the skin resulting from the increased blood supply.

The treatment usually results in an improved skin appearance and also improved skin conditioning.

The immediate glowing feeling is also greatly appreciated by most patients treated in this manner and such patients generally perceive their treated skin as being fresher, cleaner and glowing with health. The skin also is a healthy pink colour which patients have regarded favourably.

Claims

WHAT I CLAIM IS:

1.A topical application for skin care comprising a rubifacient and vasodilatory agent mixed with a keratolytic and desquamating agent in a compatible base to a strength suitable to an individual's requirements.

2.A topical application, according to Claim 1, in which the rubifacient and vasodilatory agent is a nicotinic acid derivative.

3.A topical application, according to Claim 2, in which the nicotinic acid derivative is nicotinic acid at a concentration of between .01% and 20 > .

4.A topical application, according to Claim 3, in which the concentration of the nicotinic acid is between .1% and 5%.

5.A topical application, according to Claim 3, in which the concentration of the nicotinic acid is between 1% and 20h 6.A topical application, according to Claim 2, in which the nicotinic acid derivative is a nicotinate from the group including methyl nicotinate, benzyl nicotinate, ethyl nicotinate, butoxyethyl nicotinate and thurfyl nicotinate at a concentration of between .01 and 20%.

7.A topical application, according to Claim 6, in which the concentration of the nicotinate is between .1 and 5%.

8.A topical application, according to Claim 6, in which the concentration of the nicotinate is between 1% and 2%.

90A topical application, according to any preceding claim, in which the keratolytic and desquamating agent is a peroxide.

10.A topical application, according to Claim 9, in which the peroxide is benzoyl peroxide at a concentration of 1* and 30%.

11.A topical application, according to Claim 10, in which the concentration of the benzoyl peroxide is between 1* and 200h 12.A. topical application, according to any preceding claim, in which the base is an aqueous cream with cetyl alcohol and cetomacrogol emulsifying wax.

13. A topical application for skin care substantially as described herein.